Abraxis BioScience, TRSI Enter Agreement for Epothilone Therapeutic

Abraxis BioScience and The Scripps Research Institute (TRSI) announced their exclusive licensing agreement for the worldwide development and commercialization of a novel epothilone therapeutic for the treatment of cancer.

Epothilones belong to a new class of microtubule-stabilizing agents, which bind to the tubulin pathway to inhibit the growth and proliferation of cancer cells.

Under the terms of the agreement, Abraxis said it has rights to eleven potential drug candidates for preclinical evaluation and selection of a lead candidate for clinical development.

The companies did not disclose the financial terms of the agreement.